It has been universally recognized that simply targeting systemic hyperglycaemia and metabolic disorders is not sufficient to arrest the progression of DN, indicating that there must be other molecular mechanism responsible for therapeutic effects of PTPN2 for DN. This evidence concerns the gene PTPN2 and Other metabolic disease.